Healthpeak (DOC) Shares Rise 6.3% Following Last Earnings Announcement: Will the Momentum Persist?

Healthpeak Outperforms S&P 500 with Recent Gains

Over the past month, Healthpeak (DOC) shares have climbed approximately 6.3%, surpassing the performance of the S&P 500 during the same period.

Will Healthpeak's Momentum Last?

As Healthpeak approaches its next earnings announcement, investors are wondering if the upward trend will persist or if a correction is on the horizon. Before examining recent analyst and investor sentiment, let's review the latest quarterly results to understand the key factors at play.

Q4 Results: Earnings Surpass Expectations, NOI Grows

In the fourth quarter of 2025, Healthpeak Properties posted adjusted FFO per share of $0.47, exceeding the Zacks Consensus Estimate of $0.45 and improving from $0.46 in the same quarter last year.

This outperformance was driven by stronger-than-anticipated revenue and an increase in total merger-combined same-store cash (adjusted) NOI. However, higher interest expenses weighed on the results.

Total revenue reached $719.4 million, topping the consensus estimate of $699.5 million and marking a 3.1% increase year over year.

Additionally, Healthpeak announced plans to launch Janus Living, Inc., a new senior housing REIT, through an initial public offering.

Key Details from the Earnings Report

• Total merger-combined same-store cash (adjusted) NOI grew 3.9% year over year in Q4.
• The outpatient medical segment saw a 4.1% increase, while the life plan segment surged 16.7%. The lab segment, however, declined by 0.3%.
• During the quarter, Healthpeak signed new and renewal leases covering 333,000 square feet in its lab portfolio, with renewal leases experiencing a negative 1.7% cash-releasing spread.
• In the outpatient medical portfolio, new and renewal leases totaled 1.8 million square feet, with renewal leases achieving a positive 4.4% cash-releasing spread.
• Interest expenses rose 14.4% year over year to $80.6 million.

Financial Position

At the end of Q4, Healthpeak held $467.5 million in cash and cash equivalents, a significant increase from $91 million at the end of September 2025. The company's net debt to adjusted EBITDAre stood at 5.2x as of December 31, 2025.

2026 Guidance

• Healthpeak projects adjusted FFO per share to range between $1.70 and $1.74 for 2026.
• Growth in total merger-combined same-store cash (adjusted) NOI is expected to fall between -1% and 1%.

Recent Estimate Trends

Over the past month, analyst estimates for Healthpeak have generally moved lower.

VGM Score Overview

Currently, Healthpeak receives a D for Growth and an F for Momentum, while its Value Score stands at C, placing it in the middle 20% of this investment strategy. The overall VGM Score is D, which is most relevant for investors not focused on a single strategy.

Stock Outlook

Analyst estimates for Healthpeak have been trending downward, indicating a less optimistic outlook. The stock holds a Zacks Rank #3 (Hold), suggesting expectations for average performance in the coming months.

Industry Comparison: Prologis Performance

Healthpeak operates within the Zacks REIT and Equity Trust - Other sector. In the past month, Prologis (PLD), another company in this industry, has gained 6.9%. Prologis reported quarterly revenue of $2.09 billion, up 8% year over year, with EPS at $1.49 compared to $1.50 a year earlier.

For the current quarter, Prologis is forecasted to earn $1.48 per share, a 4.2% increase from the prior year. The Zacks Consensus Estimate for Prologis has edged down by 0.1% over the past 30 days. The stock also carries a Zacks Rank #3 (Hold) and a VGM Score of F.